XIA Guang-rong,LIU Gui-mei,JIN Guo-hua.Clinical study on tumor radiosensitizer CMNa[J].Chinese Journal of Radiological Medicine and Protection,2006,26(5):470-472
Clinical study on tumor radiosensitizer CMNa
Received:January 17, 2006  
DOI:
KeyWords:Radiotherapy  CMNa  Radiosensitizer
FundProject:
Author NameAffiliation
XIA Guang-rong Department of Radiation Oncology, Beijing Thoracic Tumor and Tuberculosis Hospital, Beijing 101149, China 
LIU Gui-mei Department of Radiation Oncology, Beijing Thoracic Tumor and Tuberculosis Hospital, Beijing 101149, China 
JIN Guo-hua Department of Radiation Oncology, Beijing Thoracic Tumor and Tuberculosis Hospital, Beijing 101149, China 
Hits: 2991
Download times: 1718
Abstract::
      Objective To verify the role of glycodidazolum natrium (CMNa) in enhancing radiosensitivity of tumors. Methods A double-blind randomized clinical trial was performed. Fifty-five cancer cases of the lungs or esophagus were randomly classified into two groups, one group (Group A) was treated with radiotherapy plus CMNa, and the control group (Group B) with radiotherapy plus placebo. Radiotherapy was administered by conventional schedule: 2 Gy per fraction, 5 fractions per week, 60~70 Gy in total during 6~7 weeks. CMNa was given by intravenous drip at a dose of 800 mg/m2 on day 1,3,and 5 per week throughout the course of treatment. Radiotherapy was started 30-60 minutes after completion of CMNa infusion. Results Among the patients of lung cancer, the CR+PR rate was 42% in Group A and 53% in Group B, respectively (P=0.516). Among the patients of esophageal carcinoma, the CR+PR rate was 100% in Group A and 43% in Group B, respectively (P=0.015). The mean survival time in Group A was 11 months, and 10 months in Group B. The 1-, 3-, and 5-year local control rates were 32%, 18%, 16% in Group A, and 28%, 19%, 13% in Group B, respectively; and the difference of local control rates between the two groups were not statistically significant (P=0.518). The 1-, 3-, and 5-year survival rates were 31%, 13% and 10% in Group A and 25%, 15% and 6% in Group B (P=0.475). There was no serious side-effect. Conclusions CMNa increased the radiotherapeutic effect in the treatment of esophageal carcinoma, but almost no effect for lung cancer. CMNa administered with radiotherapy was also well-tolerated. Long-term effect was not satisfactory. Further study with large sample-size is needed.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:9070817  On-line:0

v
Scan QR Code
&et=3C06DB566315F8DC59AE367DE863DD0B16FF9C72E2478D805D68AE4EF0BDF86363565D61A2632ED6DD6B6D770D053D44&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=37904DC365DD7266&aid=FE9AE2B9DB18266C&vid=&iid=94C357A881DFC066&sid=47F7649551A37CFC&eid=7D1E6EEC2019967D&fileno=20060517&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="37904DC365DD7266"; var my_aid="FE9AE2B9DB18266C";